Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

被引:191
作者
Jacobs, Joannes F. M. [1 ,2 ,3 ]
Nierkens, Stefan [1 ]
Figdor, Carl G. [1 ]
de Vries, I. Jolanda M. [1 ,2 ]
Adema, Gosse J. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Tumour Immunol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, NL-6500 HB Nijmegen, Netherlands
关键词
METASTATIC MELANOMA; IN-VIVO; SUPPRESSIVE FUNCTION; CANCER-PATIENTS; TUMOR-IMMUNITY; INDOLEAMINE 2,3-DIOXYGENASE; MONOCLONAL-ANTIBODY; MALIGNANT-MELANOMA; ANTITUMOR IMMUNITY; CUTANEOUS MELANOMA;
D O I
10.1016/S1470-2045(11)70155-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy studies in patients with melanoma have reported success in the expansion of tumour-specific effector T cells in vivo, but even in the presence of substantial numbers of functional T cells circulating in the blood, favourable clinical outcomes are scarce. This failure to induce robust clinical responses might be related to tumour-induced immune evasion, rendering the host tolerant to melanoma antigens. Immunosuppression in the tumour microenvironment mediated by regulatory T cells (Treg) is a dominant mechanism of tumour immune escape and is a major hurdle for tumour immunotherapy. Accumulation of Treg in melanoma is frequently recorded and the ratio of CD8-positive T cells versus Treg in the tumour microenvironment is predictive for survival of patients with melanoma. Hence, depletion of Treg seems to be a promising strategy for the enhancement of melanoma-specific immunity. Indeed, murine studies have shown that Treg depletion greatly increases the efficacy of immunotherapy. But despite the success of some strategies in depletion of Treg in patients, overall clinical efficacy has been disappointing. The lack of Treg specificity of the Treg depleting strategies applied so far imply that well-designed studies into dosage, timing, and administration regimens with more specific agents are urgently needed. Depletion of functional Treg from the tumour microenvironment as part of multifaceted immunotherapeutic treatments is a major challenge to induce clinically relevant immune responses against melanomas.
引用
收藏
页码:E32 / E42
页数:11
相关论文
共 79 条
[1]   IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].
Ahmadzadeh, M ;
Rosenberg, ST .
BLOOD, 2006, 107 (06) :2409-2414
[2]   FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions [J].
Ahmadzadeh, Mojgan ;
Felipe-Silva, Aloisio ;
Heemskerk, Bianca ;
Powell, Daniel J., Jr. ;
Wunderlich, John R. ;
Merino, Maria J. ;
Rosenberg, Steven A. .
BLOOD, 2008, 112 (13) :4953-4960
[3]   Immunotherapy for Melanoma: Current Status and Perspectives [J].
Alexandrescu, Doru T. ;
Ichim, Thomas E. ;
Riordan, Neil H. ;
Marincola, Francesco M. ;
Di Nardo, Anna ;
Kabigting, Filamer D. ;
Dasanu, Constantin A. .
JOURNAL OF IMMUNOTHERAPY, 2010, 33 (06) :570-590
[4]   Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma [J].
Attia, P ;
Maker, AV ;
Haworth, LR ;
Rogers-Freezer, L ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :582-592
[5]   DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells [J].
Baron, Udo ;
Floess, Stefan ;
Wieczorek, Georg ;
Baumann, Katrin ;
Gruetzkau, Andreas ;
Dong, Jun ;
Thiel, Andreas ;
Boeld, Tina J. ;
Hoffmann, Petra ;
Edinger, Matthias ;
Tuerbachova, Ivana ;
Hamann, Alf ;
Olek, Sven ;
Huehn, Jochen .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (09) :2378-2389
[6]  
BERD D, 1986, CANCER RES, V46, P2572
[7]   Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine [J].
Beyer, M ;
Kochanek, M ;
Darabi, K ;
Popov, A ;
Jensen, M ;
Endl, E ;
Knolle, PA ;
Thomas, RK ;
von Bergwelt-Baildon, M ;
Bebey, S ;
Hallek, M ;
Schultze, JL .
BLOOD, 2005, 106 (06) :2018-2025
[8]   Human T cell responses against melanoma [J].
Boon, Thierry ;
Coulie, Pierre G. ;
Van den Eynde, Benoit J. ;
van der Bruggen, Pierre .
ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :175-208
[9]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[10]   Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival [J].
Brody, Jonathan R. ;
Costantino, Christina L. ;
Berger, Adam C. ;
Sato, Takami ;
Lisanti, Michael P. ;
Yeo, Charles J. ;
Emmons, Robert V. ;
Witkiewicz, Agnieszka K. .
CELL CYCLE, 2009, 8 (12) :1930-1934